Key facts
- GeneCapture’s last known valuation is $23.5M (Sep 2021).
- It has raised $7.4M across 2 recorded rounds; the latest was Seed Round ($500K) in Nov 2024.
- Notable investors include United States Department of War, First Avenue Ventures, Air Force Research Laboratory, Alabama Launchpad, Coplanar Capital — 11 tracked in total.
- GeneCapture has filed 10 Form Ds with the SEC since 2012, most recently Dec 2024 ($500K sold to 1 investors).
- Status: Privately Held (backing).
Investors
11+- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for GeneCapture
Funding rounds
2 roundsAbout GeneCapture
Developer of a medical diagnostic device designed to detect and identify pathogens and to bring infection detection to the point of care. The company's device screens germs in blood, urine and wounds against a wide array of genetic signatures and reports the results within an hour, enabling medical professionals to detect bacterial and viral infections in a portable instrument for use in clinics, field applications, airports and at borders.
- Sector
- Healthcare
- HQ
- Huntsville, AL, United States
- Founded
- 2009
- Employees
- 23
- Website
- genecapture.com/
- Ownership
- Privately Held (backing)
GeneCapture doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneCapture shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneCapture in its N-PORT filings yet. We sweep new filings monthly.